Researchers connect haywire protein to breast cancer, leukemia

May 7, 2015, The Scripps Research Institute
A Wright's stained bone marrow aspirate smear from a patient with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk/Wikipedia

A new study led by scientists at The Scripps Research Institute (TSRI) sheds light on the cause of some cancers, including breast cancer and leukemia.

In the new study, the researchers found that too much of a key protein, called cyclin E, slows down DNA replication and introduces potentially harmful cancer-linked mutations when divide.

"Overexpression of cyclin E is one route to cancer," said TSRI Professor Steven Reed, senior author of the new study.

The findings were published May 7, 2015 in the journal Current Biology.

A Good Protein Gone Bad

A cell must copy its DNA before dividing into two identical . Each round of comes with the risk of DNA replication errors—the chance that some areas might be duplicated, deleted or out of order.

In , cyclin E binds to and activates an enzyme, Cdk2, which begins the DNA replication process. Cells need just the right amount of cyclin E to divide properly. Unfortunately, some genetic mutations can cause too much cyclin E to be produced in cells.

Reed and his colleagues at TSRI originally discovered cyclin E, and previous studies led by Reed's lab showed that abnormally high levels of cyclin E are associated with chromosome instability, increasing the chances that a chromosome will acquire more mutations as it divides. Researchers have found that cyclin E is frequently overexpressed in cancer cells and that overexpression is linked to a decreased survival rate for breast cancer patients.

Until this new study, scientists did not know exactly how cyclin E introduces chromosome instability and errors into DNA.

DNA 'Tug-of-War'

The researchers investigated the role of cyclin E by comparing normal human mammary cells with human mammary cells forced to overexpress cyclin E at the same levels seen in some .

In an experiment spearheaded by TSRI Research Associate Leonardo Teixeira, now at the Brazilian National Cancer Institute, the researchers found DNA replication took significantly longer in the cyclin E-deregulated cells. In fact, the cells seemed to enter the next stage of cell division before the DNA was even done replicating. Intriguingly, they found that a small number (16) of very specific regions on the chromosomes frequently had failed to complete replication.

The researchers then screened the cyclin E-deregulated cells for errors later in the cell division process, when the original cell begins to pull apart into separate daughter cells. Visualizing chromosomes marked with a fluorescent protein, they found that the chromosomes of the daughter cells of the cyclin E-deregulated cells stuck together in the spots where replication had not finished.

"You could see a tug-of-war going on," said Reed. "That would cause either the chromosome to tear or both chromosomes to go to one side." The researchers spotted abnormal DNA "bridges" tying daughter cells together—they even saw cells where chunks of chromosomes ripped away and floated nearby. After these abnormal divisions took place, a third of the cyclin E-deregulated cells showed DNA deletions at the specific regions identified previously as having a tendency to not finish replication prior to cell division.

The Link to Cancer

Next, the researchers investigated how the genetic instability from DNA deletions in cyclin E-deregulated cells could contribute to cancer.

Interestingly, many of the sites with DNA deletions were areas in which DNA was already known to be fragile or difficult to replicate.

Using a database of tumor DNA sequences, they found that six of the 16 DNA regions they had identified in their cell-based studies showed damage in breast tumors that could be directly linked to cyclin E overexpression. One area commonly damaged in cyclin E-deregulated cells even matched up with an area commonly rearranged in a type of leukemia called mixed lineage leukemia, where cyclin E had already been shown to be a contributing factor.

One of the unanswered questions posed by this work is how cells are allowed to divide before all the chromosomes are completely replicated. It had been believed that "checkpoints" exist to prevent such accidents from happening. Reed believes that these unreplicated regions are small enough to bypass the cellular "checkpoints" and keep cells dividing under such circumstances and accumulating potentially harmful mutations.

Reed said the next step for his team is to sequence the entire genomes of cells that undergo damage from cyclin E overexpression to understand exactly how the deletions contribute to cancer.

Explore further: Cancer protein discovery may aid radiation therapy

Related Stories

Cancer protein discovery may aid radiation therapy

June 9, 2011
Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.

In a bizarre twist, Cyclin D, long believed to promote cancer, actually activates tumor suppressor

July 2, 2014
Researchers at the University of California, San Diego School of Medicine say a protein essential to regulating cell cycle progression – the process of cell division and replication – activates a key tumor suppressor, ...

Dual role: Key cell division proteins also power up mitochondria

April 17, 2014
An international team led by researchers at UC Davis has shown that the cyclin B1/Cdk1 protein complex, which plays a key role in cell division, also boosts the mitochondrial activity to power that process. This is the first ...

Cyclin D1 governs microRNA processing in breast cancer

November 29, 2013
Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA (miRNA), according to new research publishing November 29 in Nature Communications. ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.